Tanya Siddiqi

Associate Professor

City Of Hope National Medical Center

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (15)

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Collaborators (11)

Constantine S. Tam

AUSTRALIA

View details

Lihua Budde

Associate Professor

City Of Hope National Medical Center

UNITED STATES

View details

Monica Saumoy

University of Pennsylvania

UNITED STATES

View details

David B Miklos

UNITED STATES

View details

Olalekan O Oluwole

Vanderbilt University Medical Center

UNITED STATES

View details

Ken Ogasawara

Bristol-Myers Squibb

UNITED STATES

View details

Paolo Ghia

ITALY

View details

Paul M. Barr

University of Rochester

UNITED STATES

View details

William Wierda

Professor of Medicine

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Ranjana Advani

Saul A. Rosenberg Professor of Lymphoma

UNITED STATES

View details

Deborah Stephens

Assistant Professor

Huntsman Cancer Institute

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Tanya Siddiqi

Research Interests

Explore related searches

Contact this professor

Articles (15)

CARs vs bispecifics: the race is on!

Acalabrutinib-based regimens in frontline or relapsed/refractory higher-risk CLL: pooled analysis of 5 clinical trials

Advancing CAR T-cell therapy for chronic lymphocytic leukemia: exploring resistance mechanisms and the innovative strategies to overcome them

Lisocabtagene Maraleucel in Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis of the Mantle Cell Lymphoma Cohort From TRANSCEND NHL 001, a Phase I Multicenter Seamless Design Study

Absence of BTK, BCL2, and PLCG2 Mutations in Chronic Lymphocytic Leukemia Relapsing after First-Line Treatment with Fixed-Duration Ibrutinib plus Venetoclax

Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia

Venetoclax in Previously Treated Waldenström Macroglobulinemia

Cost-effectiveness of polatuzumab vedotin combined with chemoimmunotherapy in untreated diffuse large B-cell lymphoma

Cost-effectiveness of second-line axicabtagene ciloleucel in relapsed refractory diffuse large B-cell lymphoma

Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL

Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort

Management of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in the Era of Targeted Therapies

CD19-directed CAR T-cell therapy for treatment of primary CNS lymphoma

Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study

Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma

Collaborators (11)

Constantine S. Tam

Lihua Budde

Monica Saumoy

David B Miklos

Olalekan O Oluwole

Ken Ogasawara

Paolo Ghia

Paul M. Barr

William Wierda

Ranjana Advani

Deborah Stephens

Make your next move.